Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

More than 1.2 million people die each year as a direct result of antibiotic-resistant bacterial infections. But this number could soon rise dramatically: as resistance spreads, an increasing number of infections are becoming harder – and sometimes impossible – to treat as antibiotics become less effective.

A hand with a petri dish with some samples

‘Antibiotic resistance is already a major challenge and one that is growing fast. Without effective action, we could soon be in a “post-antibiotic era”, where even minor cuts and common infections could be fatal, and standard medical procedures become highly risky,’ said Harrison Steel, Associate Professor of Engineering Science at the University of Oxford.

To address this threat, in September 2023 President Biden announced a new Defeating Antibiotic Resistance through Transformative Solutions (DARTS) project. Backed by up to $104 million of funding, it is the largest investment made to date by the USA’s Advanced Research Projects Agency for Health (ARPA-H).

The aim of DARTS is to combine the power of artificial intelligence (AI), high-throughput testing and robotics to develop rapid platforms to test for antibiotic resistance. Led by Harvard Medical School, DARTS brings together more than twenty partners in the United States. As the only non-US partner in the project, Professor Steel’s research group was invited to participate due to its world-leading expertise in developing robotic applications to address biological challenges.

Read the full story on the University of Oxford website.

Similar stories

Wellcome Discovery Award of £5m to fund pioneering research to combat deadly diarrhoea

The Ineos Oxford Institute has been awarded a £5 million Wellcome Discovery Award to develop vaccines against pathogens that cause diarrhoea - the third most common cause of death for children under five years of age. The work will be led by Professor Sam Sheppard, Principal Investigator of IOI’s digital microbiology programme.